A detailed history of Opaleye Management Inc. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 395,276 shares of KROS stock, worth $22.4 Million. This represents 4.19% of its overall portfolio holdings.

Number of Shares
395,276
Previous 367,500 7.56%
Holding current value
$22.4 Million
Previous $16.8 Million 36.67%
% of portfolio
4.19%
Previous 4.3%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $1.16 Million - $1.61 Million
27,776 Added 7.56%
395,276 $23 Million
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $412,600 - $704,800
10,000 Added 2.8%
367,500 $24.3 Million
Q4 2023

Feb 14, 2024

SELL
$27.12 - $41.05 $78,648 - $119,044
-2,900 Reduced 0.8%
357,500 $14.2 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $244,667 - $333,405
7,750 Added 2.2%
360,400 $11.5 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $4.27 Million - $5.85 Million
114,650 Added 48.17%
352,650 $14.2 Million
Q4 2022

Feb 10, 2023

SELL
$39.45 - $51.77 $3.29 Million - $4.31 Million
-83,300 Reduced 25.93%
238,000 $11.4 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $1.26 Million - $1.82 Million
45,300 Added 16.41%
321,300 $12.1 Million
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $266,807 - $687,160
10,250 Added 3.86%
276,000 $7.63 Million
Q4 2021

Feb 14, 2022

SELL
$36.95 - $62.89 $3.21 Million - $5.46 Million
-86,750 Reduced 24.61%
265,750 $15.5 Million
Q3 2021

Nov 16, 2021

BUY
$29.27 - $43.71 $3.44 Million - $5.14 Million
117,500 Added 50.0%
352,500 $13.9 Million
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $3.29 Million - $5.43 Million
77,500 Added 49.21%
235,000 $9.98 Million
Q1 2021

May 18, 2021

BUY
$54.0 - $75.28 $8.51 Million - $11.9 Million
157,500 New
157,500 $9.69 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.46B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.